Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below Two Hundred Day Moving Average – Here’s Why

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.04 and traded as low as $6.78. Karyopharm Therapeutics shares last traded at $7.66, with a volume of 233,130 shares traded.

Analysts Set New Price Targets

A number of research analysts recently commented on KPTI shares. HC Wainwright upped their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, Robert W. Baird cut their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Karyopharm Therapeutics Price Performance

The firm has a 50 day simple moving average of $9.43 and a 200-day simple moving average of $10.97. The stock has a market capitalization of $63.40 million, a price-to-earnings ratio of -7.38 and a beta of 0.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. On average, sell-side analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $27,000. Focus Partners Wealth bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $31,000. TD Waterhouse Canada Inc. bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $32,000. Two Sigma Advisers LP grew its holdings in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $85,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).